Jennifer Tate Brasseaux
Optometrist · Opelousas, LANPI 1881884245
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,309 of the $2,893 with a category attached, or 79.8%. It is spread thinly across 17 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations.
Across 42 payments — averaging $68.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$490
- Maculogix, Inc.$474
- Optos, Inc.$354
- Coopervision Inc.$331
- Dompe US, Inc.$185
- Sun Pharmaceutical Industries Inc.$179
- plus $881 from 11 others
Across 24 payments — averaging $33.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Notal Vision, Inc.$810
What the payments were for
- Consulting fees$30010%
- Speaking & faculty fees$502%
- Food & beverage$2,30980%
- Gifts$191%
- Entertainment$2157%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 6 | $490 |
| Maculogix, Inc. | 3 | $474 |
| Optos, Inc. | 3 | $354 |
| Coopervision Inc. | 10 | $331 |
| Dompe US, Inc. | 2 | $185 |
| Sun Pharmaceutical Industries Inc. | 2 | $179 |
| Sight Sciences, Inc. | 1 | $148 |
| Tarsus Pharmaceuticals, Inc. | 2 | $127 |
| LKC Technologies, Inc. | 1 | $119 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $115 |
| Glaukos Corporation | 1 | $111 |
| Mallinckrodt Hospital Products Inc. | 1 | $95 |
| AbbVie(2 entities) | 3 | $84 |
| Notal Vision, Inc. | 2 | $32 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Bausch & Lomb Americas Inc. | 1 | $16 |
| Biotissue Holdings Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AdaptDx$424
- PANORAMIC OPHTHALMOSCOPE$317
- OCT OPHTHALMOSCOPE$317
- Hydrus Microstent$278
- NFC-700$159
- TEARCARE SYSTEM$148
- P200DTx$139
- P200T$139
- P200TE$139
- P200TxE$139
- Precision 1$121
- Biofinity Contact Lens$117
- Photrexa Viscous and Photrexa$111
- XDEMVY$103
How this compares
$2,893 in reported general payments places this provider in the 70th percentile of 500 optometrist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Restasis MultidoseCyclosporine | 13 | $7,591 |
| Azelastine Hcl | 108 | $2,938 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 31 | $2,893 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $2,297 |
| Prednisolone Acetate | 48 | $2,162 |
| Latanoprost | 187 | $1,369 |
| Timolol Maleate | 18 | $637 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 24 | $551 |
| Ketorolac Tromethamine | 11 | $433 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 16 | $165 |
| Brimonidine Tartrate | 11 | $47 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis Multidose | $84 | $7,59113 claims |
| AlconSimbrinza | $490 | $2,29711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 500 optometrist providers in Louisiana.
Other optometrist in Opelousas
- Pamela TheriotShreveport$207K
- Joshua DavidsonGonzales$189K
- Jeffrey WilhiteMarrero$86K
- Christopher WrotenHammond$59K
- James LamarNew Orleans$45K
- John McCallLogansport$32K
- Robert KellyMarrero$26K
- Shane FontenotJennings$23K
- Stephen LewisShreveport$17K
- Breanne McGheeNew Orleans$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.